Business Description
Entrada Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29384C1080
Total Employee Number:
152Description
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.54 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.29 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.53 | |||||
Beneish M-Score | -0.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6.9 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | -0.5 | |||||
3-Year Book Growth Rate | 5.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.69 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.45 | |||||
9-Day RSI | 48.94 | |||||
14-Day RSI | 47.59 | |||||
3-1 Month Momentum % | -53 | |||||
6-1 Month Momentum % | -39.23 | |||||
12-1 Month Momentum % | 3.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.9 | |||||
Quick Ratio | 13.9 | |||||
Cash Ratio | 3.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 3.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3109.29 | |||||
Net Margin % | -2895.05 | |||||
EBITDA Margin % | -3040.36 | |||||
FCF Margin % | -2294.2 | |||||
OCF Margin % | -2295.22 | |||||
ROE % | -48.45 | |||||
ROA % | -40.3 | |||||
ROIC % | -144.79 | |||||
3-Year ROIIC % | -211 | |||||
ROC (Joel Greenblatt) % | -187.76 | |||||
ROCE % | -45.63 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 7.69 | |||||
PS Ratio | 50.94 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.01 | |||||
EV-to-EBIT | -1.36 | |||||
EV-to-Forward-EBIT | -1.43 | |||||
EV-to-EBITDA | -1.39 | |||||
EV-to-Revenue | 42.16 | |||||
EV-to-Forward-Revenue | 15.44 | |||||
EV-to-FCF | -1.84 | |||||
Price-to-GF-Value | 6.89 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 23.43 | |||||
Earnings Yield (Greenblatt) % | -73.53 | |||||
FCF Yield % | -48.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRDA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entrada Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.738 | ||
| EPS (TTM) ($) | -3.99 | ||
| Beta | -0.0869 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 76.17 | ||
| 14-Day RSI | 47.59 | ||
| 14-Day ATR ($) | 0.528984 | ||
| 20-Day SMA ($) | 7.2325 | ||
| 12-1 Month Momentum % | 3.22 | ||
| 52-Week Range ($) | 4.93 - 16.45 | ||
| Shares Outstanding (Mil) | 38.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entrada Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entrada Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 21 days | ||
| General meeting for 2026 | 2026-06-10 09:30 | 6.37 (-0.31%) | ||
| Guidance call for 2026 | 2026-06-08 08:00 | 6.37 (-8.08%) | ||
| Guidance call for 2026 | 2026-06-03 17:30 | 6.64 (-2.35%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 10:00 | 5.89 (-7.39%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 16.03 (+1.58%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.03 (+1.58%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 14:30 | 11.68 (-0.93%) | ||
| Annual report for 2025 | 2026-02-26 | 11.98 (+3.54%) |
Show
Entries
Entrada Therapeutics Inc Frequently Asked Questions
What is Entrada Therapeutics Inc(TRDA)'s stock price today?
The current price of TRDA is $7.03. The 52 week high of TRDA is $16.45 and 52 week low is $4.93.
When is next earnings date of Entrada Therapeutics Inc(TRDA)?
The next earnings date of Entrada Therapeutics Inc(TRDA) is 2026-08-06 Est..
Does Entrada Therapeutics Inc(TRDA) pay dividends? If so, how much?
Entrada Therapeutics Inc(TRDA) does not pay dividend.
Guru Commentaries on NAS:TRDA
No articles.
Press Release
Articles on Entrada Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers